Results 281 to 290 of about 3,159,718 (373)

Deciphering cell cycle organization of <i>Toxoplasma</i> endodyogeny. [PDF]

open access: yesmBio
Batra M   +7 more
europepmc   +1 more source

Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF ...
Albert Aboseif   +17 more
wiley   +1 more source

Pilaralisib inhibits the replication of enteroviruses by targeting the PI3K/AKT signaling pathway. [PDF]

open access: yesVirol J
Zhou J   +10 more
europepmc   +1 more source

Effects of Pharmacologic and Nonpharmacologic Interventions for the Management of Sleep Problems in People With Fibromyalgia: Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

open access: yesArthritis Care &Research, EarlyView.
Objective Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain and fatigue. Almost everyone with fibromyalgia has sleep problems. We aimed to evaluate the effectiveness and safety of current interventions for the management of fibromyalgia‐related sleep problems.
Jemma Hudson   +11 more
wiley   +1 more source

Moderators and Mediators of Pain and Function Outcomes in a New Service Delivery Model for Management of Knee Osteoarthritis in Primary Care: Secondary Exploratory Analysis of a Randomized Controlled Trial

open access: yesArthritis Care &Research, EarlyView.
Objective Our objective was to explore moderators and mediators influenced changes in pain and function in people with knee osteoarthritis (OA) receiving a new model of primary care service delivery (Optimizing Primary Care Management of Knee Osteoarthritis [PARTNER]), at 12 months (ACTRN: 12617001595303).
Abdolhay Farivar   +12 more
wiley   +1 more source

Cost‐effectiveness of low dose colchicine prophylaxis when starting allopurinol using the “start‐low go‐slow” approach for gout: evidence from a non‐inferiority randomised double‐blind placebo‐controlled trial.

open access: yesArthritis Care &Research, Accepted Article.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy